DOCSLIB.ORG

PROGRAM/ABSTRACTS International Honorary Local Organizing Advisory Board President Committee

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PROGRAM/ABSTRACTS International Honorary Local Organizing Advisory Board President Committee PROGRAM/ABSTRACTS International Honorary Local Organizing Advisory Board President Committee Y. Agid (Paris) G.L. Gessa (Cagliari) M. Diana (Coordinator) F.E. Bloom (La Jolla) V. Bassareo (Cagliari) A. Bjorklund (Lund) C. Cadoni (Cagliari) A. Carlsson (Goteborg) Organizers A. Carta (Cagliari) M. Caron (Durham) E. Carboni (Cagliari) G.U. Corsini (Pisa) M. Diana (Sassari) M.A. De Luca (Cagliari) S.B. Dunnett (Cardiff) G. Di Chiara (Cagliari) P. Enrico (Sassari) G.L. Gessa (Cagliari) P.F. Spano (Brescia) S. Fenu (Cagliari) A.M. Graybiel (Boston) M. Melis (Cagliari) P. Greengard (New York) C. Missale (Brescia) T. Hökfelt (Stockholm) M. Morelli (Cagliari) G.F. Koob (La Jolla) A.T. Peana (Sassari) J. Mallet (Paris) G. Piras (Cagliari) T.W. Robbins (Cambridge) U. Spampinato (Bordeaux) W. Schultz (Cambridge) S. Spiga (Cagliari) T. Svensson (Stockholm) V. Valentini (Cagliari) N.D. Volkow (Bethesda) M. Zigmond (Pittsburgh) ORGANIZED UNDER THE AUSPICES OF Provincia di Sassari Università di Sassari Camera di Commercio Nord Sardegna ADDITIONAL SPONSOR EXHIBITORS ORGANIZING SECRETARIAT Address: Via Del Pozzetto 13 - 09126 Cagliari, Sardinia (Italy) Ph.: +39 070 383373 - Fax: +39 070 3837102 e-mail: [email protected] - web address: www.corsiecongressi.com PROGRAM/ABSTRACTS Dopamine 2013 Friday, MAY 24th 8:00 – 8:30 REGISTRATION 8:30 – 10:30 SESSION 1 Topic: DOPAMINE AND REWARD Room: SAYÀL ENDOCANNABINOID/DOPAMINE INTERACTIONS AND THE PURSUIT OF REWARD Chair: E.L. Gardner (USA) - Co-Chair: J.F. Cheer (USA) Organizer: J. F. Cheer (USA) -M. Melis (Italy) Enhanced 2-arachidonoylglycerol signaling in dopamine neurons as a possible marker of heightened predisposition to addiction -C. Lupica (USA) Cocaine inhibition of synaptic GABA inputs to VTA DA neurons: Roles for serotonin and endocannabinoids -L. Venance (France) Endocannabinoid and dopamine interact to mediate spike-timing dependent potentiation and depression -J.F. Cheer (USA) Endocannabinoids modulate accumbal dopaminergic encoding during signaled shock avoidance Topic: DOPAMINE AND COGNITION Room: QUARTÉ DOPAMINE – RELATED LEARNING DYSFUNCTIONS IN ADDICTION Chair: G. Hasler (Switzerland) - Co-Chair: P.N.Tobler (Switzerland) Organizer: G. Hasler (Switzerland) -P.N. Tobler (Switzerland) Role of dopamine in learning - findings from single cells and neuroimaging -S. Flagel (USA) Parsing the role of dopamine in stimulus-reward learning: Implications for Addiction -Q. Huys (UK) Learning processes in the development of addiction -G. Hasler (Switzerland) Dopaminergic dysfunction and reward learning in bulimia nervosa Topic: DOPAMINE AND AFFECTIVE DISORDERS Room: ARCHI THE ROLE OF THE DOPAMINE TRANSPORTER IN HUMAN DISEASE Chair: R.D. Blakely (USA) - Co-Chair: M. Kurian (UK) Organizer: M. Kurian (UK) -M. Reith (USA) The dopamine transporter: Structure, function and pharmacological considerations -R.D. Blakely (USA) The Role of the Dopamine Transporter in Attention Deficit/Hyperactivity Disorder -A. Galli (USA) De novo mutation in the dopamine transporter gene associates dopamine dysfunctionwith autism spectrum disorders -M. Kurian (UK) Dopamine Transporter Deficiency Syndrome: Characterisation of the Clinical and Molecular Features of this Novel "Dopamine Transportopathy Topic: DOPAMINE RECEPTORS Room: LAZZARETTO DOPAMINE RECEPTORS: NEW CELLULAR MECHANISMS RELEVANT FOR CNS DISORDERS Chair: P. Sokoloff (France) - Co-Chair: B. Le Foll (Canada) Organizer: B. Le Foll (Canada) -G. Collo (Italy) Critical role of dopamine D3 receptor in structural plasticity generated by exposure to drugs of addiction in mesencephalic dopaminergic neurons -B. Le Foll (Canada) Neuronal circuitry underlying the impact of dopamine D3 receptors ligands on drug addiction -E.A. Rabiner (UK) Evaluation of the Dopamine D3 receptor in the living brain with [11C]-(+)-PHNO PET -I. Boileau (Canada) Imaging D3 dopamine receptor levels across behavioral and drug addiction: positron emission tomography / [11C]-(+)-PHNO studies -E. Merlo-Pich (Italy) Pharmacological targeting of Dopamine D3 receptor: a review of therapeutic applications 10:30 – 11:00 COFFEE BREAK 1 Dopamine 2013 11:00 – 13:00 SESSION 2 Topic: DOPAMINE NEURONS Room: LAZZARETTO IS OUR LIFE STYLE KILLING OUR DOPAMINE NEURONS? Chair: M.J.Zigmond (USA) - Co-Chair: U. Spampinato (France) Organizer: M.J.Zigmond (USA) -F. Cicchetti (Canada) Impact of n-3 PUFA in Parkinson's Disease: evidence from animal models -V.A. Russel (South Africa) Interactions between early stress and exercise in a rat model of Parkinson's Disease -J.L. Cameron (USA) Physical activity protects the striatum against damage in nonhuman primates -M.J. Zigmond (USA) Neurotrophic factors: a link between life style and the health of dopamine neurons? Topic: DOPAMINE AND NEUROPLASTICITY Room: QUARTÉ NEW INSIGHTS INTO THE DEVELOPMENT AND PLASTICITY OF DOPAMINE CONNECTIVITY Chair: C. Flores (Canada) - Co-Chair: P. Henny Vargas (Chile) Organizer: C. Flores (Canada) -P. Henny Vargas (Chile) Structural and synaptic substrates of activity in dopaminergic neurons -J. Pasterkamp (Netherlands) Molecular and genetic dissection of dopaminergic pathway development -C. Bellone (Switzerland) Drug-evoked synaptic plasticity in the VTA: a role for calcium-impermeable, GluN3A-containing NMDARs -C. Flores (Canada) Netrin-1 receptors organize mesocortical dopamine circuitry during adolescence Topic: DOPAMINE AND REWARD Room: SAYÀL OPTOGENETIC PERTURBATION OF DOPAMINE NEURONAL CIRCUITRY Chair: A. Bonci (USA) - Co-Chair: G. Stuber (USA) Organizer: G. Stuber (USA) -L. Kravitz (USA) Dissecting the striatal contributions to reinforcement and punishment -N. Uchida (USA) Dissecting computations in the dopamine reward circuit -T. Kash (USA) Genetic Modulation of Periaqueductal Grey Dopamine Neurons -J. Britt (USA) The organization and behavioral consequence of discrete glutamatergic input to the nucleus accumbens -G. Stuber (USA) Dissecting the neural circuitry that mediates reward and aversion 13:00 – 15:00 LUNCH BREAK 15:00 – 17:00 SESSION 3 Topic: DOPAMINE AND PARKINSON’S DISEASE Room: LAZZARETTO TRANSCRIPTION FACTORS AS MEDIATORS OF DOPAMINE NEURODEGENERATION IN PARKINSON'S DISEASE Chair: A. Björklund (Sweden) - Co-Chair: A. Prochiantz (France) Organizer: M. Decressac (Sweden) -T. Perlmann (Sweden) Transcription factors for the development and maintenance of dopamine neurons -A. Prochiantz (France) Traveling homeoprotein transcription factors regulate mDA survival and physiology -A. Björklund (Sweden) Nurr1 as a regulator of survival and GDNF-induced neuroprotection in adult dopamine neurons -M. Smidt (Netherlands)Pitx3 is part of a homeodomain code for dopaminergic subset specification and survival Topic: DOPAMINE AND REWARD 2 Dopamine 2013 Room: SAYÀL NUCLEUS ACCUMBENS: CORE AND SHELL SPECIALIZATION IN REWARD FUNCTION? Chair: R.A. Wise (USA) - Co-Chair: G. Di Chiara (Italy) Organizer: R.A. Wise (USA) -S. Ikemoto (USA) Drug and dopamine reward and the ventral striatum -R.A. Wise (USA) Cocaine reinforcement is a shell phenomenon; cocaine satiety involves the core -B.J. Aragona (USA) Regional specificity of real-time dopamine transmission: implications for reward and function -J.A. Dani (USA) Mechanistic Interactions between the Nicotinic Cholinergic and Dopaminergic Systems during Signaling and Synaptic Potentiation Topic: ANATOMY AND PHYSIOLOGY OF DOPAMINE SYSTEMS Room: ARCHI THALAMOSTRIATAL SYNAPSES - ANOTHER SUBSTRATE FOR DOPAMINE ACTION Chair: J.P. Bolam (UK) - Co-Chair: G.W.Arbuthnott (Japan) Organizer: G.W.Arbuthnott (Japan) -J.P. Bolam (UK) The thalamostriatal projection: a major excitatory input to the basal ganglia -G. Halliday (Australia) Impact of thalamic changes in Parkinson's disease on the motor system -J. Ding (USA) Formation and Function of Thalamostriatal Synapses on Striatal Medium Spiny Neurons and Choliergic Interneurons -K. Kobayashi (Japan) Behavioral roles of thalamostriatal pathway in sensory discrimination learning Topic: DOPAMINE AND REWARD Room: QUARTÉ INDIVIDUAL DIFFERENCES IN DOPAMINE SIGNALING: ROLE IN LEARNING, RISK TAKING, AND IMPULSIVITY Chair: A. Dagher (Canada) - Co-Chair: M. Frank (USA) Organizer: A. Dagher (Canada) -M. Frank (USA) Computational models of dopamine in learning and choice incentive -A. Gjedde (Denmark) Sensation-seeking propensity is directly proportional to dopamine storage and inversely proportional to dopamine turnover in human dorsal striatum in vivo -R. Ebstein (Singapore) Dopamine D4 Receptor (DRD4) Gene, Religious Affiliation and Spirituality Contribute to Dictator Game Altruism -M. Leyton (Canada) Vulnerability to Addictions: Dopamine Studies in Humans 17:15 – 18:15 PLENARY LECTURE: Room: SAYÀL JAMES M. TEPPER (USA) Striatal TH Interneurons: Physiology, Pharmacology and Transmitter Release Host: M. Morelli (Italy) 18:30 OPENING RECEPTION 3 Dopamine 2013 Saturday, MAY 25th 8:30 – 10:30 SESSION 1 Topic: DOPAMINE AND NEUROPLASTICITY Room: SAYÀL DOPAMINE REGULATION OF STRIATAL PLASTICITY Chair: D.M. Lovinger (USA) - Co-Chair: M.S. Levine (USA) Organizer: P. Belujon (USA) -P. Belujon (USA) Altered hippocampal-accumbens synaptic plasticity in an animal model of depression -R. Malenka (USA) Role of distinct subtypes of dopamine neurons in reward and aversion -A.A. Grace (USA) Regulation of plasticity in the nucleus accumbens by afferent input: impact of stress -J. Reynolds (New Zealand)Timing dependent effects of substantia nigra dopamine on sensory and motor reinforcement Topic: DOPAMINE AND SCHIZOPHRENIA Room: LAZZARETTO DOPAMINE-GLUTAMATE INTERACTIONS IN BRAIN
Load more

Recommended publications
  • SYNTHESIS and STRUCTURE ACTIVITY STUDIES of NOVEL H3-RECEPTOR HISTAMINE ANTAGONISTS. a Thesis Presented in Partial Fulfilment Of
    1 SYNTHESIS AND STRUCTURE ACTIVITY STUDIES OF NOVEL H3-RECEPTOR HISTAMINE ANTAGONISTS. A thesis presented in partial fulfilment of the requirements for the Doctor of Philosophy Degree of the University of London SEYED KIUMARS HOSSEINI Department of Chemistry University College London September 1991 Attention is drawn to the fact that copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that the copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without prior consent of the author. Signature: Date..^*^^~ ProQuest Number: 10609847 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10609847 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 2 Acknowledgements I would like to express my gratitude for the guidance and generous support of Prof. C. R. Ganellin and for the financial support of Bioproject in association with Centre Paul Broca de rinserm, Paris. Thanks to Prof.
    [Show full text]
  • Management of Side Effects of Antipsychotics
    Management of side effects of antipsychotics Oliver Freudenreich, MD, FACLP Co-Director, MGH Schizophrenia Program www.mghcme.org Disclosures I have the following relevant financial relationship with a commercial interest to disclose (recipient SELF; content SCHIZOPHRENIA): • Alkermes – Consultant honoraria (Advisory Board) • Avanir – Research grant (to institution) • Janssen – Research grant (to institution), consultant honoraria (Advisory Board) • Neurocrine – Consultant honoraria (Advisory Board) • Novartis – Consultant honoraria • Otsuka – Research grant (to institution) • Roche – Consultant honoraria • Saladax – Research grant (to institution) • Elsevier – Honoraria (medical editing) • Global Medical Education – Honoraria (CME speaker and content developer) • Medscape – Honoraria (CME speaker) • Wolters-Kluwer – Royalties (content developer) • UpToDate – Royalties, honoraria (content developer and editor) • American Psychiatric Association – Consultant honoraria (SMI Adviser) www.mghcme.org Outline • Antipsychotic side effect summary • Critical side effect management – NMS – Cardiac side effects – Gastrointestinal side effects – Clozapine black box warnings • Routine side effect management – Metabolic side effects – Motor side effects – Prolactin elevation • The man-in-the-arena algorithm www.mghcme.org Receptor profile and side effects • Alpha-1 – Hypotension: slow titration • Dopamine-2 – Dystonia: prophylactic anticholinergic – Akathisia, parkinsonism, tardive dyskinesia – Hyperprolactinemia • Histamine-1 – Sedation – Weight gain
    [Show full text]
  • In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists
    0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles.
    [Show full text]
  • Drug-Induced Movement Disorders
    Medical Management of Early PD Samer D. Tabbal, M.D. May 2016 Associate Professor of Neurology Director of The Parkinson Disease & Other Movement Disorders Program Mobile: +961 70 65 89 85 email: [email protected] Conflict of Interest Statement No drug company pays me any money Outline So, you diagnosed Parkinson disease .Natural history of the disease .When to start drug therapy? .Which drug to use first for symptomatic treatment? ● Levodopa vs dopamine agonist vs MAOI Natural History of Parkinson Disease Before levodopa: Death within 10 years After levodopa: . “Honeymoon” period (~ 5-7 years) . Motor (ON/OFF) fluctuations & dyskinesias: ● Drug therapy effective initially ● Surgical intervention by 10-15 years - Deep brain stimulation (DBS) therapy Motor Response Dyskinesia 5-7 yrs >10 yrs Dyskinesia ON state ON state OFF state OFF state time time Several days Several hours 1-2 hour Natural History of Parkinson Disease Prominent gait impairment and autonomic symptoms by 20-25 years (Merola 2011) Behavioral changes before or with motor symptoms: . Sleep disorders . Depression . Anxiety . Hallucinations, paranoid delusions Dementia at anytime during the illness . When prominent or early: diffuse Lewy body disease Symptoms of Parkinson Disease Motor Symptoms Sensory Symptoms Mental Symptoms: . Cognitive and psychiatric Autonomic Symptoms Presenting Symptoms of Parkinson Disease Mood disorders: depression and lack of motivation Sleep disorders: “acting out dreams” and nightmares Early motor symptoms: Typically Unilateral . Rest tremor: chin, arms or legs or “inner tremor” . Bradykinesia: focal and generalized slowness . Rigidity: “muscle stiffness or ache” Also: (usually no early postural instability) . Facial masking with hypophonia: “does not smile anymore” or “looks unhappy all the time” .
    [Show full text]
  • 2009 Paris, France the Movement Disorder Society’S 13Th International Congress of Parkinson’S Disease and Movement Disorders
    FINAL PROGRAM The Movement Disorder Society’s 13th International Congress OF PARKINSon’S DISEASE AND MOVEMENT DISORDERS JUNE 7-11, 2009 Paris, France The Movement Disorder Society’s 13th International Congress of Parkinson’s Disease and Movement Disorders Claiming CME Credit To claim CME credit for your participation in the MDS 13th International Congress of Parkinson’s Disease and Movement Disorders, International Congress participants must complete and submit an online CME Request Form. This Form will be available beginning June 10. Instructions for claiming credit: • After June 10, visit www.movementdisorders.org/congress/congress09/cme • Log in following the instructions on the page. You will need your International Congress Reference Number, located on the upper right of the Confirmation Sheet found in your registration packet. • Follow the on-screen instructions to claim CME Credit for the sessions you attended. • You may print your certificate from your home or office, or save it as a PDF for your records. Continuing Medical Education The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation The Movement Disorder Society designates this educational activity for a maximum of 30.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Non-CME Certificates of Attendance were included with your on- site registration packet. If you did not receive one, please e-mail [email protected] to request one. The Movement Disorder Society has sought accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
    [Show full text]
  • Substituted 3-Isobutyl-9, 10-Dimethoxy-1,3,4,6,7,11B
    (19) TZZ Z_ 9B_T (11) EP 2 081 929 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 471/04 (2006.01) 09.01.2013 Bulletin 2013/02 (86) International application number: (21) Application number: 07864160.2 PCT/US2007/084176 (22) Date of filing: 08.11.2007 (87) International publication number: WO 2008/058261 (15.05.2008 Gazette 2008/20) (54) SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO SUBSTITUIERTE 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOCHINOLIN-2-OLVERBINDUNGEN UND DIESE BETREFFENDE VERFAHREN COMPOSÉS 3-ISOBUTYL-9, 10-DIMÉTHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL SUBSTITUÉS ET PROCÉDÉS ASSOCIÉS (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • BROSSIA ET AL: "SYNTHESEVERSUCHE IN DER HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE EMETIN-REIHE 3. MITTEILUNG 2-HYDROXY- SI SK TR HYDROBENZOÄAÜCHINOLIZINE" HELVETICA Designated Extension States: CHIMICA ACTA, VERLAG HELVETICA CHIMICA AL BA HR MK RS ACTA. BASEL, CH, vol. 41, no. 4, 1958, pages 1793-1806, XP008047475 ISSN: 0018-019X (30) Priority: 08.11.2006 US 864944 P • KILBOURN M R ET AL: "Absolute Configuration of (+)-alpha-Dihydrotetrabenazine, an Active (43) Date of publication of application: Metabolite of Tetrabenazine" CHIRALITY, WILEY- 29.07.2009 Bulletin 2009/31 LISS, NEW YORK, US, vol.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Tetrabenazine: the First Approved Drug for the Treatment of Chorea in US Patients with Huntington Disease
    Neuropsychiatric Disease and Treatment Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW 7HWUDEHQD]LQHWKHÀUVWDSSURYHGGUXJ for the treatment of chorea in US patients with Huntington disease Samuel Frank Abstract: Huntington disease (HD) is a dominantly inherited progressive neurological disease Boston University School of Medicine, characterized by chorea, an involuntary brief movement that tends to flow between body regions. Boston, Massachusetts, USA HD is typically diagnosed based on clinical findings in the setting of a family history and may be confirmed with genetic testing. Predictive testing is available to those at risk, but only experienced clinicians should perform the counseling and testing. Multiple areas of the brain degenerate mainly involving the neurotransmitters dopamine, glutamate, and G-aminobutyric acid. Although pharmacotherapies theoretically target these neurotransmitters, few well-conducted trials for symptomatic or neuroprotective interventions yielded positive results. Tetrabenazine (TBZ) is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects. Some newer antipsychotic agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable adverse-effect profile than older antipsychotic agents for treating chorea and psychosis. This review will address the epidemiology and diagnosis of HD as background for understanding potential pharmacological treatment options. Because TBZ is the only US Food and Drug Administration-approved medication in the United States for HD, the focus of this review will be on its pharmacology, efficacy, safety, and practical uses. There are no current treatments to change the course of HD, but education and symptomatic therapies can be effective tools for clinicians to use with patients and families affected by HD.
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
    [Show full text]
  • Pathology, Prevention and Therapeutics of Neurodegenerative Disease
    Pathology, Prevention and Therapeutics of Neurodegenerative Disease Sarika Singh Neeraj Joshi Editors 123 Pathology, Prevention and Therapeutics of Neurodegenerative Disease Sarika Singh • Neeraj Joshi Editors Pathology, Prevention and Therapeutics of Neurodegenerative Disease Editors Sarika Singh Neeraj Joshi Toxicology and Experimental Department of Surgery Medicine Division Samuel Oschin Comprehensive Cancer CSIR-Central Drug Research Institute Institute, Cedar Sinai Medical Center Lucknow Los Angeles, CA India USA ISBN 978-981-13-0943-4 ISBN 978-981-13-0944-1 (eBook) https://doi.org/10.1007/978-981-13-0944-1 Library of Congress Control Number: 2018952338 © Springer Nature Singapore Pte Ltd. 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]
  • Clinical Study Protocol with Amendment 3 an Open-Label
    Clinical Study Protocol with Amendment 3 An Open-Label, Long Term Safety Study of SD-809 ER in Subjects with Chorea Associated with Huntington Disease Study SD-809-C-16 NCT01897896 Protocol with Amendment 3 Approval Date: 2 March 2015 &21),'(17,$/ 7KHIROORZLQJFRQWDLQVFRQILGHQWLDOSURSULHWDU\LQIRUPDWLRQZKLFKLVWKHSURSHUW\RI $XVSH[3KDUPDFHXWLFDOV,QF 35272&2/180%(56'& $123(1/$%(//21*7(506$)(7<678'<2)6'(5,1 68%-(&76:,7+&+25($$662&,$7(':,7+ +817,1*721',6($6( $OWHUQDWLYHVIRU5HGXFLQJ&KRUHDLQ+XQWLQJWRQ'LVHDVH $5&+' 0DUFK $PHQGPHQW 'HYHORSPHQW3KDVH Auspex Pharmaceuticals, Inc. Protocol SD-809-C-16 Huntington Study Group ARC-HD STUDY CONTACTS SPONSOR: Auspex Pharmaceuticals, Inc. 3333 N. Torrey Pines Court, Suite 400 La Jolla, CA 92037 USA Principal Investigator Co-Principal Investigator CLINICAL MONITOR Amendment 3 CONFIDENTIAL 2 Auspex Pharmaceuticals, Inc. Protocol SD-809-C-16 Huntington Study Group ARC-HD PROTOCOL SYNOPSIS PROTOCOL SD-809-C-16 TITLE An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease Running Title Alternatives for Reducing Chorea in HD (ARC-HD) PHASE 3 (Safety) INDICATION Treatment of chorea associated with Huntington disease NO. SITES Approximately 40 OBJECTIVES 1) Evaluate the safety and tolerability of titration and maintenance therapy with SD-809 ER 2) Evaluate the safety and tolerability of switching subjects from tetrabenazine to SD-809 ER 3) Evaluate the pharmacokinetics of tetrabenazine, SD-809 and their respective α- and β-HTBZ metabolites in subjects switching from tetrabenazine to SD-809 ER STUDY Approximately 116 male and female adult subjects with manifest Huntington disease POPULATION (HD) who are receiving approved doses of tetrabenazine for treatment of chorea (approx.
    [Show full text]
  • Metabolic Enzyme/Protease
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
    [Show full text]